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Abstract
Background: The concept of 'avoidable' mortality (AM) has been proposed as a performance
measure of health care systems. In this study we examined mortality in five geographic regions of
Canada from 1975 to 1999 for previously defined avoidable disease groups that are amenable to
medical care and public health. These trends were compared to mortality from other causes.
Methods: National and regional age-standardized mortality rates for ages less than 65 years were
estimated for avoidable and other causes of death for consecutive periods (1975–1979, 1980–1985,
1985–1989, 1990–1994, and 1995–1999). The proportion of all-cause mortality attributable to
avoidable causes was also determined.
Results:  From 1975–1979 to 1995–1999, the AM decrease (46.9%) was more pronounced
compared to mortality from other causes (24.9%). There were persistent regional AM differences,
with consistently lower AM in Ontario and British Columbia compared to the Atlantic, Quebec,
and Prairies regions. This trend was not apparent when mortality from other causes was examined.
Injuries, ischaemic heart disease, and lung cancer strongly influenced the overall AM trends.
Conclusion: The regional differences in mortality for ages less than 65 years was attributable to
causes of death amenable to medical care and public health, especially from causes responsive to
public health.
Background
Rising health care costs and concern regarding the per-
formance of health services has led to the development of
various indicators of health care quality. In 1976, the
Working Group on Preventable and Manageable Diseases
proposed using "unnecessary untimely deaths" as an indi-
cator of medical care quality [1]. The Working Group pre-
sented lists of conditions for which deaths may be
amenable if appropriate medical care is provided in a
timely fashion. The 'avoidable' mortality (AM) concept
has since been applied in various investigations examin-
ing differences in mortality between regions and over
time.
Temporal trend analyses have demonstrated remarkable
declines in AM over the past decades that were much more
pronounced when compared to mortality from other
causes [2-5]. In the Netherlands, Mackenbach et al[6]
demonstrated that declines in mortality from avoidable
causes of death were preceded by the introduction of suc-
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cessful medical interventions for those causes. These
observations have been used to argue that improvements
in medical care have contributed to mortality declines.
Following this reasoning, regional comparisons of AM
have been conducted in order to highlight areas with
excess mortality and stimulate further inquiry so that
appropriate measures can be taken [7,8]. More recently,
the AM concept has been extended to include causes of
death amenable to public health [9,10]. AM has been pro-
posed as a population-based performance measure for
Canada's health care system[11,12].
The objective of this study was to examine mortality
trends from avoidable causes of death in Canada. We
examined mortality from 1975–1979 to 1995–1999 in
five geographic regions of Canada. These trends were
compared to mortality from other causes of death not
classified as avoidable. In addition, we investigated the
contribution of each avoidable condition to all-cause
mortality in Canada.
Methods
Mortality data were obtained from the Canadian Mortal-
ity Database. The selection of avoidable causes of death
was based on disease and age groups proposed by the
Concerted Action of the European Community on
"Avoidable Deaths" with the addition of lung cancer and
injuries (see Table 1)[13,11]. The conditions were catego-
rized as causes amenable to medical care or public health.
Deaths amenable to medical care are those for which it is
reasonable to expect deaths to be averted after the condi-
tion has developed. This list includes causes such as
Table 1: Selected avoidable deathsa
Cause of death Intervention Evidence of 
effectiveness
ICD8 code
1969–78
ICD9 code
1979–99
Age-groups
(years)
All causes 000–999 001–999 0–64
Ischaemic heart disease Public health 
Smoking cessation, lifestyle 
modification
[21][22][36] 410–413 410–414,
429.2
35–64
Medical care 
Pharmacotherapy, angioplasty, 
surgery
[37][38][39][40][41]
Deaths amenable to medical care
Tuberculosis Immunization, contact tracing, 
pharmacotherapy
[42][43] 011–019 010–018,
137
5–64
Malignant neoplasm of the breast 
[Breast cancer]
Screening, surgery, radiation 
therapy, chemotherapy
[44][45][46][47] 174 174 25–64
Malignant neoplasm of the cervix uteri 
[Cervical cancer]
Screening, surgery, radiation 
therapy, chemotherapy
[48][49] 180 180 15–64
Malignant neoplasm of the uterus 
(except cervix uteri) [Uterine cancer]
Screening, surgery, radiation 
therapy, chemotherapy
[50][51] 182 179, 182 15–64
Hodgkin's disease Chemotherapy, radiation therapy [52][53][54] 201 201 15–64
Hypertension and cerebrovascular 
disease
Pharmacotherapy, carotid 
endarterectomy
[39][55][56][57] 400–404,
430–438
401–405,
430–438
35–64
Asthma Pharmacotherapy [58][59] 493 493 5–44
Gastric and duodenal ulcer [Ulcers] Pharmacotherapy, surgery [60][61] 531–534 531–534 25–64
Appendicitis Surgery [62][63] 540–543 540–543 5–64
Hernia Surgery [64] 550–553 550–553 5–64
Cholelithiasis, cholecystitis and 
cholangitis [Gallbladder diseases]
Pharmacotherapy, surgery [65] 574–576 575–476 5–64
Complications of pregnancy [Maternal 
mortality]
Screening, pharmacotherapy, 
surgery
[66][67] 630–678 630–676 0–64
Perinatal conditions Screening, pharmacotherapy, 
surgery
[68] 760–779 760–779 > 28 weeks
gestation <1
week and
stillbirths
Deaths amenable to public health
Malignant Neoplasm of the Trachea, 
Bronchus and Lung [Lung cancer]
Smoking cessation, lifestyle 
modification
[69][70][71] 162 162 35–64
Accidents/Poisonings/Violence 
[Injuries]
Legislation, safety equipment [72][73][74][75][76][7
7][20]
800–999 800–999 0–64
Note – Simplified names for some causes are presented within square brackets.
aAdapted from the European Community Working Group on Health Services and "Avoidable Deaths," 1997.[16]BMC Public Health 2006, 6:137 http://www.biomedcentral.com/1471-2458/6/137
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appendicitis and asthma, where the medical nature of the
intervention is evident. This list also includes causes such
as cervical and breast cancer, where deaths are preventable
through early detection and effective treatment. Deaths
amenable to public health are those for which medical
care may be less effective for treating the condition, but
where there are interventions that are known to prevent
the condition from occurring. This group includes deaths
from lung cancer, which are mainly amenable to lifestyle
changes (mainly tobacco use), and deaths from injuries,
which are influenced by social safety programs and legis-
lative measures. Ischaemic heart disease (IHD) was cate-
gorized separately because both medical care and public
health can contribute to reducing deaths from IHD [14].
Evidence demonstrating that the causes of death are ame-
nable to health care interventions are referenced. The
deaths that were not classified as avoidable were classified
as deaths from other causes.
The data analyses were restricted to deaths under 65 years
of age, since health care can have the greatest impact on
preventing deaths in this group. Deaths from other causes
were calculated as the difference between all-cause deaths
and avoidable deaths. There are various conditions that
are amenable to health care but have not previously been
included in avoidable deaths classification lists. Although
this is partly due to data availability and/or accuracy
issues, this also reflects differences in opinions regarding
the preventability of certain causes of death as well as the
role of public health and medical care in avoiding
deaths[15,16]. For this study, causes of death were
selected according to an established and widely dissemi-
nated list of avoidable deaths created by the European
Community.
The trends in age-standardized mortality from avoidable
and other causes of death were estimated for five geo-
graphic regions of Canada for consecutive periods (1975–
1979, 1980–1985, 1985–1989, 1990–1994, and 1995–
1999). The Atlantic region included the provinces Prince
Edward Island, Newfoundland, Nova Scotia and New
Brunswick. The Prairies region consisted of the provinces
Manitoba, Saskatchewan and Alberta. Age-standardized
mortality rates (ASMRs) were derived using the direct
method with Canada 1991 as the reference population.
Mortality trends are presented with 95% confidence inter-
vals assuming that the number of deaths in each age group
follow a Poisson distribution.
Time trends for regional mortality from 'avoidable' and other  causes from 1975 to 1999 Figure 2
Time trends for regional mortality from 'avoidable' 
and other causes from 1975 to 1999. Abbreviation: 
ASMR = age-standardized mortality rate (per 100,000 popu-
lation).
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Mortality from 'avoidable' and other causes in Canada from  1975 to 1999 Figure 1
Mortality from 'avoidable' and other causes in Can-
ada from 1975 to 1999. 
Abbreviation: ASMR = age-standardized mortality rate (per 
100,000 population).
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Results
Figure 1 shows the avoidable and other cause mortality
trends in Canada from 1975–1979 to 1995–1999. During
this time, mortality from avoidable and other causes
decreased. However, the decline in AM (46.9%) was more
pronounced from 1975–1979 to 1995–1999 compared to
mortality from other causes (24.9%).
Figure 2 illustrates avoidable and other cause mortality
trends in the five regions of Canada. For AM, there was a
persistent difference between the highest and lowest
Canadian region since 1980–1984. Ontario and British
Columbia had consistently lower AM trends than the
other regions. For other causes, there was a narrowing of
provincial differences over the study period. By 1990–
1994 provincial differences for other causes was small.
Table 2 and Table 3 describe the mortality trends from
each avoidable cause of death for males and females in
Canada and the proportion of all-cause mortality under
65 years of age attributable to each avoidable cause. With
the exception of lung cancer, mortality from these causes
decreased from 1975–1979 to 1995–1999. The relative
decrease in mortality from avoidable causes from 1975–
1979 to 1995–1999 was similar between males and
females. Lung cancer mortality increased by 79.7% in
females but decreased from 1980–1984 onward in males
for an overall decrease of 21.5%.
From 1975–1979 to 1995–1999, the proportion of all-
cause mortality attributable to avoidable causes of death
decreased for males (63.3% to 52.6%) and females
(54.4% to 50.2%). During 1995–1999, the avoidable
causes that contributed the most to all-cause under 65
mortality were injuries, ischaemic heart disease and lung
cancer, together contributing 41.3% to all-cause mortal-
ity. For females, breast cancer accounted for 10.6% of
under 65 mortality during 1995–1999. Hypertension and
cerebrovascular disease and perinatal mortality also con-
tributed considerably to all-cause mortality during 1995–
1999 (3.0% and 2.3%, respectively).
Figures 3, 4, 5, 6, 7 and 8 present the time trends for mor-
tality from the avoidable causes of death that contributed
at least 1% to all-cause mortality under 65 years of age in
Canada during 1995–1999. Cause-specific mortality for
both sexes was combined, except for deaths from lung
cancer (figure 3) and breast cancer (figure 4). The largest
regional differences were for injuries (figure 5) and lung
cancer (males). Lung cancer for women was the only
avoidable cause where mortality differences had increased
over time, with increasing mortality in the Quebec and
Prairies regions compared to decreasing mortality since
1990–1994 in all other regions. Large differences in
regional mortality from ischaemic heart disease (figure 6)
continued throughout the study period, although these
differences narrowed over time.
Table 2: All-cause mortality under 65 years and 'avoidable' mortality in Canada from 1975 to 1999, malesa, b
1975–1979 1980–1984 1985–1989 1990–1994 1995–1999
Cause ASMR %d ASMR % ASMR % ASMR % ASMR % %changee
All causes 344.5 100.0 292.1 100.0 259.0 100.0 233.4 100.0 203.8 100.0 40.8
Injuries 80.1 23.3 67.1 23.0 57.2 22.1 50.9 21.8 46.4 22.8 42.0
I s c h a e m i c  h e a r t  d i s e a s e 8 9 . 62 6 . 07 0 . 72 4 . 25 4 . 52 1 . 04 0 . 41 7 . 33 2 . 21 5 . 8 6 4 . 0
Lung cancer 23.1 6.7 24.9 8.5 24.5 9.5 22.3 9.6 18.1 8.9 21.5
Hypertension and cerebrovascular disease 12.5 3.6 9.3 3.2 7.4 2.9 6.5 2.8 5.4 2.7 56.9
Perinatal conditions 9.2 2.7 6.4 2.2 5.1 2.0 4.2 1.8 3.9 1.9 57.3
Ulcers 1.2 0.3 0.9 0.3 0.7 0.3 0.5 0.2 0.3 0.2 71.7
Hodgkin's disease 0.8 0.2 0.7 0.2 0.6 0.2 0.4 0.2 0.3 0.2 62.3
Asthma 0.2 0.1 0.3 0.1 0.3 0.1 0.2 0.1 0.1 0.1 38.0
Gallbladder diseases 0.4 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.1 58.6
Tuberculosis 0.6 0.2 0.4 0.1 0.2 0.1 0.2 0.1 0.1 0.0 84.5
Hernia 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 54.7
Appendicitis 0.2 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 82.1
"Avoidable" causes 218.1 63.3 181.1 62.0 150.8 58.2 125.8 53.9 107.2 52.6 50.8
Other causes 126.4 36.7 111.0 38.0 108.1 41.8 107.6 46.1 96.6 47.4 23.6
a The age-groups considered for each cause of death are presented in Table 1.
b Causes are presented from the greatest contribution to all-cause mortality during 1995–1999.
c Age-standardized mortality rate (per 100,000 population).
d Percent of all cause ASMR attributed to each cause.
e Percent change in ASMR from 1975–1979 to 1995–1999.BMC Public Health 2006, 6:137 http://www.biomedcentral.com/1471-2458/6/137
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Discussion
This study shows that, while AM has decreased considera-
bly from 1975 to 1999 and regional differences in AM
have narrowed, there continues to exist important
regional disparities in AM across Canada. Consistently
lower AM trends were observed in Ontario and British
Columbia – the regions with the highest life expectancy.
Ontario experienced the lowest mortality from injuries.
British Columbia experienced the lowest mortality from
IHD. Both Ontario and British Columbia shared the low-
est lung cancer mortality experience with the Prairies. By
1995–1999, these regions showed only small differences
in mortality from other causes.
Injuries leading to death include falls, motor vehicle acci-
dents, drowning, burns, bicycle crashes and suicide. Since
deaths from these causes can potentially be prevented,
various Canadian authors have advocated for the develop-
ment of co-ordinated injury prevention and safety promo-
tion policies [17,18]. Surveillance and research aimed at
determining risk factors associated with injuries in Can-
ada have also been recommended[19]. Bicycle safety leg-
islation represents a good example of a successful
intervention for reducing injuries. Using data from the
Canadian Institute for Health Information, Macpherson
et al [20] demonstrated that bicycle-related head injury
rates were found to decrease significantly (45% reduction)
in provinces where bicycle helmet legislation had been
adopted compared to those provinces and territories
where it had not been adopted (27% reduction).
Regional variations in deaths from ischemic heart disease
have been shown to be associated with differences in the
prevalence of smoking, obesity, hypertension and physi-
cal inactivity [21,22]. Thus future efforts aiming to reduce
the regional burden of heart disease should include indi-
vidual and community-based strategies targeting the
reduction of these risk factors. Modifying these risk factors
also offers the potential for even larger gains in reducing
the total burden of disease because heart disease risk fac-
tors are also associated with deaths from other chronic
conditions, such as diabetes and cancer[23].
Tobacco use accounts for the majority of deaths from lung
cancer. Trends in lung cancer mortality reflect the smok-
ing behaviour of the population two decades earlier.
Among women, smoking rates peaked in the 1970s and
lung cancer deaths continued to increase during the
Table 3: All-cause mortality under 65 years and 'avoidable' mortality in Canada from 1975 to 1999, femalesa, b
1975–1979 1980–1984 1985–1989 1990–1994 1995–1999
Cause ASMR %d ASMR % ASMR % ASMR % ASMR % %changee
All causes 175.6 100.0 152.4 100.0 138.5 100.0 126.7 100.0 116.9 100.0 33.4
Injuries 27.9 15.9 22.4 14.7 18.9 13.7 16.3 12.9 15.0 12.8 46.3
Breast cancer 16.0 9.1 15.3 10.1 15.7 11.3 14.2 11.2 12.4 10.6 22.5
Lung cancer 6.7 3.8 8.9 5.8 10.9 7.8 11.9 9.4 12.0 10.2 -79.7
Ischaemic heart disease 22.1 12.6 17.9 11.7 14.0 10.1 10.7 8.4 8.7 7.4 60.7
Hypertension and cerebrovascular disease 9.6 5.5 7.4 4.9 5.8 4.2 4.6 3.7 4.2 3.6 56.8
Perinatal mortality 7.1 4.0 4.9 3.2 3.8 2.8 3.4 2.7 3.3 2.8 53.4
Cervical cancer 4.0 2.3 1.1 0.7 2.8 2.0 0.9 0.7 2.4 2.0 41.8
Hodgkin's disease 0.5 0.3 0.4 0.3 0.3 0.2 0.2 0.2 0.2 0.2 61.4
Ulcers 0.4 0.3 0.4 0.3 0.3 0.2 0.2 0.2 0.2 0.1 65.3
Asthma 0.2 0.1 0.3 0.2 0.3 0.2 0.2 0.2 0.1 0.1 37.9
Gallbladder diseases 0.3 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 57.0
Maternal mortality 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 48.2
Tuberculosis 0.3 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 75.9
Hernia 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.0 54.2
Appendicitis 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 57.1
"Avoidable" causes 95.5 54.5 79.6 52.2 73.2 52.8 63.1 49.8 58.7 50.2 38.5
Other causes 80.0 45.6 72.8 47.8 65.4 47.2 63.6 50.2 58.2 49.8 27.3
aThe age-groups considered for each cause of death are presented in Table 1.
b Causes are presented from the greatest contribution to all-cause mortality during 1995–1999.
c Age-standardized mortality rate (per 100,000 population).
d Percent of all cause ASMR attributed to each cause.
e Percent change in ASMR from 1975–1979 to 1995–1999.BMC Public Health 2006, 6:137 http://www.biomedcentral.com/1471-2458/6/137
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1990s. Among men, however, smoking rates peaked in
the 1960s and lung cancer death rates peaked in the
1980s, falling consistently since then[24].
In addition to traditional risk factors, broader determi-
nants of health, such as income status, employment and
education have been shown to be associated with mortal-
ity from injuries, IHD and lung cancer[21,22,17,25]. For
example, Filate et al[21] have shown that regional death
rates from ischaemic heart disease in Canada are signifi-
cantly associated with regional differences in postsecond-
ary education, unemployment rate and low income rate.
Brownell, Frisen and Mayer[17] demonstrated that geo-
graphic variations in childhood injury mortality and hos-
pitalizations in Manitoba were strongly influenced by
regional differences in neighbourhood income.
A common characteristic of these causes is the potential
contribution of public health in their control. Injuries,
along with tobacco-related causes of death, may be the
most significant deaths that could be prevented through
public health initiatives in Canada [11]. Wigle et al [26]
estimated that about half of the annual premature deaths
in Canada may be avoidable through the control of smok-
ing, diet, elevated serum cholesterol, hypertension, diabe-
tes, and alcohol. The notable regional mortality
disparities related to these causes present a warning signal
to the Canadian health care system and warrants further
investigation.
AM can be considered a useful tool that can provide
insights into health care and indicate where further
research is warranted [1,27,28]. As others have stated, sev-
eral characteristics of AM suggest that it is a useful measure
of health care performance[29,30]. First, AM one of the
few measures that can be measured over time and for dif-
ferent regions both nationally in Canada and internation-
ally. Second, death is an important outcome. This study's
findings support the use of AM as a performance measure,
particularly when used to compare health regions in Can-
ada. We show that AM in Canada appears to be a surpris-
ingly sensitive measure – one that has considerable
variation over time and across regions, and that it likely
reflects observed underlying mortality risks that are ame-
nable to public health and health care interventions.
However, AM trends should be interpreted with caution.
The definition of avoidable deaths varies between studies
and it has recently been shown that observed AM trends
are influenced by the list of avoidable deaths applied[31].
'Avoidable' mortality from breast cancer in Canada from  1975 to 1999 Figure 4
'Avoidable' mortality from breast cancer in Canada 
from 1975 to 1999. The age-groups considered for each 
cause of death are presented in Table 1. Abbreviation: ASMR 
= age-standardized mortality rate (per 100,000 population).
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'Avoidable' mortality from lung cancer in Canada from 1975  to 1999 Figure 3
'Avoidable' mortality from lung cancer in Canada 
from 1975 to 1999. The age-groups considered for each 
cause of death are presented in Table 1. Abbreviation: ASMR 
= age-standardized mortality rate (per 100,000 population).
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In addition, in this study there was a large reduction in
mortality not defined avoidable. Many deaths from these
conditions were likely amenable to health care interven-
tions. We elected to replicate a previously established list
of avoidable deaths to reduce the potential bias of select-
ing causes of death that would favour one region over
another. Future studies should include standard lists of
avoidable deaths that are periodically updated as proven
health care interventions are effectively introduced.
The AM concept implies that deaths from the selected
avoidable causes could have been avoided by optimum
health care alone. This is questionable as mortality can be
viewed as a long-term outcome that is affected by many
factors, including disease incidence, disease severity and
risk factors. Additionally, it is difficult to clearly attribute
AM trends to specific aspects of health care. It is also
important to note that some death that were classified as
avoidable may not have been preventable due to factors
such as the presence of co-morbidity or treatment compli-
cations[13,14]. A meaningful association between AM
levels and health care performance and accessibility is
lacking[32,30], and thus the validity of AM as an indicator
of health care effectiveness is unproven. Furthermore,
there are many important functions of the health care
services (such as reducing avoidable morbidity and
improving quality of life) that cannot be measured using
mortality statistics [29,27].
It has been suggested that differences in medically amena-
ble mortality rates may reflect differences in disease inci-
dence. Some authors have attempted to address this
potential limitation. For example, Treurniet et al[33]
found that regional differences in medically amenable
mortality in the Netherlands persisted after adjusting for
incidence variations. Some authors have argued that AM
trends should not be adjusted for disease incidence or risk
factors, since they related to the population's health needs
and are within the responsibility of the health system[27].
Future research should seek to understand the relation-
ship between AM levels and health care interventions.
Thus far, the association between AM and health care var-
iables have has been characterized as weak and inconsist-
ent[34]. However, the studies conducted in this area used
ecological data and considered crude measures of health
care. Further, in many countries, mortality trends are
taken into account when allocating health care resources.
As suggested by Mackenbach et al[34], individual-level
data will be necessary in order to determine whether
avoidable deaths can be linked to deficiencies in the
organization, quality or accessibility of health care serv-
ices.
Setting age-restrictions for each cause of death is a crude
approach to defining avoidable deaths. A useful alterna-
tive approach would be to perform sensitivity analyses by
comparing trends using alternative age-limits. Further-
more, calculating the proportion of avoidable deaths that
are attributable to specific health care interventions may
provide more meaningful information for health care
decision-makers regarding which interventions would
have the greatest impact on improving health and reduc-
ing inequalities. For example, in New Zealand, Tobias and
'Avoidable' mortality from ischaemic heart disease in Canada  from 1975 to 1999 Figure 6
'Avoidable' mortality from ischaemic heart disease in 
Canada from 1975 to 1999. The age-groups considered 
for each cause of death are presented in Table 1. Abbrevia-
tion: ASMR = age-standardized mortality rate (per 100,000 
population).
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'Avoidable' mortality from injuries in Canada from 1975 to  1999 Figure 5
'Avoidable' mortality from injuries in Canada from 
1975 to 1999. The age-groups considered for each cause of 
death are presented in Table 1. Abbreviation: ASMR = age-
standardized mortality rate (per 100,000 population).
Injuries 
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Jackson [35] weighted cause-specific mortality trends by
the extent to which deaths could be avoided through pri-
mary, secondary and tertiary interventions. This expan-
sion of the AM concept can be used to estimate the
potential contribution of specific health care interven-
tions to future population health gain.
Conclusion
Although regional AM differences across Canada have
decreased, there continues to exist important regional AM
disparities that are mainly attributable to causes of death
(injuries, IHD and lung cancer) mainly preventable
through public health initiatives.
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